Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.6    
    

 
  WASHINGTON MUTUAL, INC.
  PERFORMANCE SHARE PROGRAM
  AWARD TERMS AND CONDITIONS
  (200    -200     Performance Period)    

        Washington Mutual, Inc. (the "Company"), by action of the Board and approval of its shareholders,
established the Washington Mutual, Inc. 2003 Equity Incentive Plan (the "Plan"). The Company or a Related Company employs the Participant, and
the Company desires to motivate the Participant for the purposes stated in Section 1 of the Plan. In furtherance of the foregoing, the Committee (as defined in the Plan) has authorized the
grant of a Restricted Stock Unit Award to the Participant under the Company's PERFORMANCE SHARES PROGRAM, on the terms set forth in these terms and conditions and the Notice of Award delivered to the
Participant herewith. Together, these terms and conditions and the Notice of Award set forth the terms under which shares of the Company's Common Stock (or cash in lieu thereof) may be paid to the
Participant based upon the Company's performance over a three-year period. Capitalized terms not defined in these terms and conditions shall have the meaning set forth in the Plan. 

1.     Grant of Award  

        The Participant has been granted a Restricted Stock Unit Award under Section 9 of the Plan (the "Award")
with respect to the number of shares of Common Stock set forth on the Notice of Award delivered to Participant herewith. Under the Award, the Participant is eligible to receive between zero and 250%
(the "Payout Percentage") of the target number of shares subject to the Award, as such number may be adjusted or reduced as provided for herein, based
upon the Company's performance over a three-year period set forth on Participant's Notice of Award (the "Performance Period") under the
performance criteria (the "Performance Goals") set forth on Exhibit A hereto with respect to such Performance Period. 

2.     Determination and Payment of Award  

 2.1    Award Determination  

        Following the last day of the Performance Period and the collection of relevant data necessary to determine the extent to which the Performance Goals have been
satisfied, the Committee will determine: (a) the extent to which the Performance Goals were achieved by the Company for the Performance Period; (b) the Payout Percentage for the
Performance Period; and (c) the number of shares of Common Stock to be issued (or in the Committee's discretion to be used for purposes of calculating the amount payable in cash) including
dividend equivalents, upon payment of each Award for such Performance Period. The Committee shall make these determinations in its sole discretion. The number and kind of shares subject to or paid out
under the Award shall be subject to adjustment as provided for in Section 15 of the Plan. 

        Notwithstanding
the level of performance achieved under the Performance Goals and the Payout Percentage, the number of shares to be issued upon payment of each Award may be adjusted
upward or downward, including to zero, on the basis of such further consideration as the Committee shall determine, in its sole discretion, including as a result of a violation of the Company's Code
of Conduct or as other disciplinary actions[, provided that no such adjustment shall be made after a Change in Control (as defined in Section 5 below)]. However, the
Committee may not, in any event, increase the amount earned upon satisfaction of any Performance Goal by any Covered Employee, as that term is defined in the Plan. Decisions of the Committee shall be
final, conclusive and binding on all persons, including the Company, any Participant, any person claiming thereunder and any stockholder. 

 

 2.2    Dividends  

        Dividend equivalents will be paid on the number of shares actually paid under the Award as determined under Section 2.1 above (which will be calculated
based on dividends actually paid on such number of shares over the Performance Period) and will be paid in additional shares of Common Stock
or in cash (calculated by dividing the amount of dividend equivalents by the closing stock price on the date of the Committee's determination set forth in Section 2.1), unless the Committee
determines otherwise. 

 2.3    Payment of Award and Distribution of Shares  

        At the determination of the Committee, the Award may be paid in shares of Common Stock or in cash. Awards are rounded up to the next whole share value. Awards
(including dividend equivalents thereon) are paid and any shares of Common Stock thereunder are issued as soon as administrative arrangements for such are made following the completion of the
three-year performance period and the determinations of the Committee provided for herein (typically in March or April after the end of the Performance Period). 

 2.4    Determination Notice  

        The Company will notify a Participant of the Committee's determination (the "Determination Notice") of the Award
to be paid to the Participant, and the basis for such determination, including the Performance Goals level achieved by the Company for the Performance Period and the Payout Percentage for the
Performance Period. 

3.     Transfer Restrictions  

        No Award or interest in an Award may be sold, assigned, pledged or transferred by a Participant prior to the payment of shares or cash following completion of a
Performance Period; and any attempted assignment or alienation shall be strictly prohibited and void; provided, however, that: (a) a Participant may designate, on a Company-approved form, one
or more beneficiaries to receive payment under an Award after the Participant's death (if no beneficiary has been designated, all such amounts will be paid to the beneficiary designated under the
401(k) Plan of the Company or its subsidiaries or, if there is no such beneficiary designation, to the Participant's estate pursuant to the Participant's will or the applicable laws of descent and
distribution); and (b) Awards may be deferred under the Washington Mutual Deferred Compensation Plan in effect at the time of the Award payment, provided that elections to defer all or part of
an Award must be received by a Deferred Compensation Administrator at such times as the Company may from time to time specify. 

4.     Change in Job Status  

 4.1    Termination of Service  

        In general, a Participant must be employed by the Company on a full-time basis in a position eligible for participation in the Company's Performance
Shares Program, as established from time to time by the Committee, through the last day of the Performance Period in order to receive payment for Awards. Accordingly, unless otherwise amended or
stated in the terms of an individual Notice of Award or in this Section 4, in the event of any Termination of Service, a Participant shall forfeit the Award, including any accrued dividend
equivalents, without payment of any further consideration to the Participant. 

2

 

 4.2    Retirement  

        If a Participant's Termination of Service occurs due to Retirement, the Participant will not forfeit the Award and shall remain eligible for payment of the full
amount payable under the Award as if he or she had remained an employee through the last day of the Performance Period. For purposes of this section 4.2 "Retirement" shall mean separation from
service at or after age 55 with 10 years of service. The Award will be paid to the Participant at the same time that Awards are paid to actively employed participants after completion of the
Performance Period. 

 4.3    Disability or Death  

        If a Participant's Termination of Service occurs due to the Participant's Disability or death, any amount otherwise payable under the Award will be prorated based
upon the number of full weeks that the Participant was actively employed (i.e., prior to the date of the Termination of Service) during the Performance Period and will be paid to the Participant (or
the Participant's beneficiary or personal
representative in the case of death) at the same time that Awards are paid to actively employed participants after completion of the Performance Period. 

 4.4    Move to a Non-Eligible Job  

        If a Participant ceases to be employed in a position eligible to participate in the Company's Performance Shares Program, as established from time to time by the
Committee, due to a change in the Participant's position with the Company that is not otherwise a Termination of Service, any amount otherwise payable under the Award will be prorated based upon the
number of full weeks that the Participant was an eligible employee during the Performance Period and will be paid to the Participant at the same time that Awards are paid to eligible participants
after completion of the Performance Period. 

 4.5    Exercise of Discretion  

        The Committee may, at its discretion, choose to allow a Participant to remain eligible to receive the full amount payable for the Performance Period under the
Award upon such terms as it deems appropriate even if a Termination of Service occurs for reasons other than those set forth in Section 4.2, 4.3 or 4.4. In addition, the Committee (or, with
respect to a Participant who is not an executive officer of the Company, the chief human resources officer of the Company or other person performing that function) shall determine the effect on the
Award of a Company-approved leave of absence or if a Participant works less than full-time. 

5.     Change in Control  

        Subject to Section 8 below, upon the occurrence of a "change in control," a Participant will receive a prorated payment for the Award as soon as reasonably
possible following the date of the change in control based on the performance measured or estimated by the Committee through the date of the change in control or the last month- or
quarter-end preceding the date of the change in control. For this purpose, the term "change in control" shall have the meaning set forth in any individual agreement between the Participant
and the Company addressing Awards, if applicable, or in the absence thereof shall mean a Company Transaction, as defined in the Plan. 

6.     Withholding and Disposition of Shares  

        By accepting the Award, Participant agrees to make arrangements satisfactory to the Company for the payment of any federal, state, local or foreign withholding
tax obligations that arise upon receipt of the Common Stock or cash in connection with the payment of an Award. To the extent permitted by the Committee, Participant may satisfy all or part of these
obligations by paying cash to the Company, 

3

 

by
having the Company withhold an amount from any cash amounts otherwise due or to become due from the Company to the Participant, by having the Company withhold a number of shares of Common Stock
that would otherwise be issued to the Participant having a Fair Market Value sufficient to meet the tax withholding obligations, or by surrendering a number of shares of Common Stock the Participant
already owns having a Fair Market Value sufficient to meet the tax withholding obligations. If Participant does not satisfy the tax withholding obligations in a manner and time acceptable to the
Company, the Award and any shares issuable thereunder shall be forfeited. 

7.     No Contractual Rights; Status of Participant  

        No individual or Participant shall have any claim to be paid any shares of Common Stock or any amount of cash under these terms and conditions and the Notice of
Award. The Company's Performance Shares Program, these terms and conditions and the Notice of Award are not intended to vest any rights in any Participant or other person, and shall be administered by
the Committee in its complete discretion. Neither the Committee nor the Company has any obligation for uniformity of treatment of participants under the Performance Shares Program. Subject to Sections
5 and 8, at any time prior to a change in control (including after completion of the Performance Period), the Committee may amend, modify or terminate the Performance Shares Program and/or this Award. 

        Furthermore,
no aspect of the Performance Shares Program, these terms and conditions or the Notice of Award shall be deemed to constitute an employment contract or confer or be deemed to
confer on any Participant or other person any right to continue in the employ of, or to continue any other relationship with, the Company or any Related Company or limit in any way the right of the
Company or any Related Company to terminate a Participant's employment or other relationship at any time, with or without Cause. 

        Prior
to the issuance of shares of Common Stock in payment of the amount payable under the Award, if any, no shares of Common Stock will be reserved or earmarked for the Participant or
the Participant's account nor shall the Participant have any of the rights of a stockholder with respect to such shares. Upon issuance of the shares of Common Stock, if any, in payment of the Award,
Participant will be the owner of record of such shares and shall receive either (through
book-entry form) a credit to an account maintained on the Participant's behalf or a stock certificate representing such shares of Common Stock, as determined by the Committee. 

8.     Plan Controls; Effect of Individual Agreements  

        The Performance Shares Program, these terms and conditions or the Notice of Award shall be subject to the terms of the Plan, and in the event of a conflict or
ambiguity the terms of the Plan shall control. In addition, these terms and conditions or the Notice of Award shall be subject to the terms of any individual employment or other agreement between the
Company and Participant that specifically references the Performance Shares Program or the Participant's Award, and in the case of any conflict the terms of such individual agreement shall control. 

9.     General Provisions  

 9.1    Notices  

        Whenever any notice is required or permitted hereunder, such notice must be in writing and personally delivered or sent by mail. Any notice required or permitted
to be delivered hereunder shall be deemed to be delivered on the date on which it is personally delivered, or, whether actually received or not, on the third business day after it is deposited in the
United States mail, certified or registered, postage prepaid, addressed to the person who is to receive it at the address that such person has theretofore specified by written notice delivered in
accordance herewith. The Company or a Participant may change, by written notice to the other, the address for receiving notices. In the absence of contrary 

4

 

notice,
the Company may conclusively rely on an address for Participant set forth in the Company's employment records. Notices delivered to the Company shall be addressed as follows: 

	 	 	Company:	 	Washington Mutual, Inc.

Attn: Corporate Rewards, Stock Administrator

1191 Second Avenue, SAS-1610

Seattle, WA 98101

 9.2    No Waiver  

        No waiver of any provision of these terms and conditions or the Notice of Award will be valid unless in writing and signed by the person against whom such waiver
is sought to be enforced, nor will failure to enforce any right hereunder constitute a continuing waiver of the same or a waiver of any other right hereunder. 

 9.3    Entire Terms  

        Subject to Section 8, these terms and conditions and the Notice of Award set forth the entire terms of Participant's participation in the Performance
Shares Program and supercede all oral or other written agreements. 

 9.4    Successors and Assigns  

        The provisions of these terms and conditions and the Notice of Award will inure to the benefit of, and be binding on, the Company and its successors and assigns
and Participant and Participant's legal representatives, heirs, legatees, distributees, assigns, transferees by operation of law and any other person claiming rights under the Performance Shares
Program, these terms and conditions and the accompanying Notice of Award, whether or not any such person will have agreed in writing to join therein and be bound by the terms and conditions hereof. 

 9.5    Information Confidential  

        As partial consideration for receipt of the Award, the Participant agrees that he or she will keep confidential all information and knowledge that the Participant
has relating to the manner and amount of his or her participation in the Plan; provided, however, that such information may be disclosed as required by law and may be given in confidence to the
Participant's spouse, tax and financial advisors, or to a financial institution to the extent that such information is necessary to secure a loan. 

 9.6    Governing Law  

        The Performance Shares Program, these terms and conditions or the Notice of Award to the extent not otherwise governed by the laws of the United States shall be
governed by the laws of the State of Washington, without giving effect to principles of conflicts of law. 

 9.7    Interpretation and Dispute Resolution  

        All questions arising under the Plan, the Performance Shares Program, these terms and conditions or the Notice of Award shall be decided by the Committee in its
total and absolute discretion. In the event the Participant or any person claiming benefits under these terms and conditions or the Notice of Award believes that a decision by the Committee with
respect to such person was arbitrary or capricious, before the person seeks any judicial or other determination as to such matter, such person shall first petition the Committee, setting forth in
writing the basis for such belief, and the Committee shall evaluate and determine whether or not to respond to such petition. In the event of any judicial or other proceeding relating to this Award,
the substantially prevailing party in ay such dispute shall be entitled to recover reasonable attorney's fees and costs and the other party shall pay the costs of arbitration. 

        In
the event that any provision of the Plan, these terms and conditions or the Notice of Award is declared to be illegal, invalid or otherwise unenforceable by a court of competent
jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal, valid and enforceable, or otherwise deleted, and the remainder of such terms shall not be
affected except to the extent necessary to reform or delete such illegal, invalid or unenforceable provision. 

5

 
 

EXHIBIT A    
    PERFORMANCE GOALS
  (200    -200     Performance Period)    
    

        The Performance Shares Program measures Washington Mutual's performance on key financial metrics over a three-year Performance Period compared to the
performance of a peer group in the S&P Financial Index. The Human Resources Committee of the Board of Directors establishes performance measures. 

        Washington
Mutual's performance is ranked against the performance of companies in the S&P Financial Index. The ranking is based on a composite of three criteria, each of which is set
forth below together with the weight assigned to it: 

	•
	Total
Shareholder Return (TSR)—331/3%;

	•
	Return
on Equity (ROE)—331/3%; and

	•
	Earnings
per Share (EPS) growth—331/3%. 

 
 

PAYOUT SCHEDULE    
    

        Awards are based on the percentile rank of Washington Mutual performance compared to the S&P Financial Index companies as shown in the schedule below. The
weighted average percentile ranking of Washington Mutual under the three performance criteria set forth above (based on the weightings assigned above) will be calculated to determine the Payout
Percentage under the program based on the following schedule, interpolated based on actual performance (e.g., 76th percentile equals 180%
payout). 

	Percentile

Rank vs. Peers
 
	 	Percentage Payout

of Target Award
	 
	90th and above	 	250	%
	85th	 	225	%
	80th	 	200	%
	75th	 	175	%
	70th	 	150	%
	60th	 	100	%
	50th	 	75	%
	40th	 	50	%
	30th	 	25	%
	below 30th	 	0	%

 
 

WASHINGTON MUTUAL, INC.    
    NOTICE OF AWARD
  UNDER THE PERFORMANCE SHARES PROGRAM
  (200    -200     Performance Period)    
    

        Washington Mutual, Inc. (the "Company"), pursuant to the 2003 Equity Incentive Plan (the "Plan"), hereby grants you a Restricted Stock Unit Award under
Section 9 of the Plan, pursuant to the Company's Performance Shares Program as set forth below. This award is subject to all of the terms and conditions set forth in this Notice of Award, the
Award Terms and Conditions under the Performance Shares Program attached hereto (the "Agreement") and the Plan. 

	 	Participant:	    

	 	Date of Award:	    

	 	Performance Target Shares Awarded:	    

	 	Performance Period:	        From [date] to [date]

	

 	

Washington Mutual, Inc.
	

 	

By:	

    

	 	Name and Title:	    

	 	Date:	    

        Acceptance: Your right to this Award will be forfeited unless you deliver to the Company a counterpart of this Agreement duly
executed by you. By accepting this Award, you acknowledge and agree that you have been furnished a copy of and have reviewed the 2003 Equity Incentive Plan, the Award Terms and Conditions under the
Performance Shares Program, and you accept and agree to be bound by the terms thereof. You acknowledge that the Performance Shares Program is an employee benefit plan of the Company that is
administered by and can be amended, modified or terminated at any time by the Human Resources Committee of the Company's Board of Directors. If you have not received those documents, please notify
Washington Mutual Stock Administration (stock@wamu.net) immediately. 

 ACKNOWLEDGED AND AGREED  

	Participant's Signature:	    

	Print Name:	    

	Date:	    

RETURN BY FAX: 206-461-1943; OR MAIL TO: WASHINGTON MUTUAL, STOCK ADMINISTRATION, 1191 SECOND AVE, SAS 1610, SEATTLE, WA 98101  

QuickLinks

Exhibit 10.6

WASHINGTON MUTUAL, INC. PERFORMANCE SHARE PROGRAM AWARD TERMS AND CONDITIONS (200 -200 Performance Period)

EXHIBIT A PERFORMANCE GOALS (200 -200 Performance Period)

PAYOUT SCHEDULE

WASHINGTON MUTUAL, INC. NOTICE OF AWARD UNDER THE PERFORMANCE SHARES PROGRAM (200 -200 Performance Period)QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.1    
    

 
 

AMENDMENT AND PATENT ASSIGNMENT AGREEMENT    
    

        This Amendment and Patent Assignment Agreement (this "Amendment"), dated as of this 2nd day of July, 2004 (the
"Amendment Date"), is made by and between Sepracor Inc., a Delaware corporation ("Sepracor"), and
Aventis Pharma SA (successor in interest to Rhone-Poulenc Rorer SA), a corporation organized under the laws of France ("Aventis"). 

RECITALS  

A.    Sepracor
and Aventis entered into that certain License and Assignment Agreement dated as of September 30, 1999 (the "1999
Agreement"). 

B.    Aventis
owns certain patents and patent applications, if any, as more particularly described on Schedule 1.21, which are the
foreign counterparts of the RPR Application (as defined in the 1999 Agreement) assigned to Sepracor pursuant to the 1999 Agreement and certain know-how relating to (+) zopiclone, the
racemate or the other enantiomer thereof, or metabolites of any of the foregoing. 

C.    Aventis
is willing to assign the above-referenced patents and patent applications, if any, to Sepracor and license to Sepracor exclusive rights under the above-referenced
know-how to make, have made, use, market, sell, offer for sale, have sold and distribute pharmaceutical products containing (+) zopiclone worldwide, on the terms and subject to the
conditions set forth in the 1999 Agreement and this Amendment, and Sepracor is willing to accept such assignment and license. 

D.    Sepracor
is willing to allow Aventis to assign certain rights under the 1999 Agreement to a third party. 

E.    Sepracor
and Aventis wish to amend certain provisions of the 1999 Agreement as set forth specifically in this Amendment. 

        NOW THEREFORE, in consideration of the mutual promises, covenants and agreements hereinafter set forth, the sufficiency of which is hereby
acknowledged, the parties to this Amendment mutually agree as follows: 

ARTICLE 1  

 DEFINITIONS  

        Capitalized terms used herein and not otherwise defined shall have the meanings given to them in the 1999 Agreement, as amended. 

ARTICLE 2  

 AMENDMENT OF 1999 AGREEMENT  

        Effective from and after the date hereof, subject to Article 5 of this Amendment, the 1999 Agreement shall be amended as follows: 

         2.1  All
references to the defined term "RPR" shall be replaced throughout the 1999 Agreement by the term "Aventis" as defined in this Amendment. 

         2.2  Article 1
(Definitions) is hereby amended as follows: 

      2.2.1  The
definition of "Agreement" is hereby amended and restated in its entirety as follows: 

        "Agreement" shall mean this License and Assignment Agreement, as amended. 

1

 

      2.2.2  The
definition of the term "Product" is hereby amended by adding the phrase ", provided, however, that in the Additional Territory, the term "Product' shall not
include (±) zopiclone" to the end of such definition. 

      2.2.3  A
new definition of "Additional Patents" is hereby added as Section 1.21 as follows: 

        "Additional Patents" shall mean French Patent Application No. 91-00490 and PCT International Patent Application No.
PCT/FR92/00031 (collectively "Priority Applications"), and any patents and patent applications (whether pending, lapsed, or abandoned) in the Additional Territory claiming benefit of at least one
Priority Application, including without limitation, those described on Schedule 1.21 hereto, and any and all additions, divisions, continuations,
continuations-in-part, reissues, reexaminations, substitutions, supplemental protection certificates, extensions, patent term extensions, and renewals thereof, and patents
issued therefrom, which are the foreign counterparts of the RPR Application. 

      2.2.4  A
new definition of "Additional Territory" is hereby added as Section 1.22 as follows: 

        "Additional Territory" shall mean all of the countries in the world and their territories and possessions, other than the United States of
America and its territories and possessions. 

      2.2.5  A
new definition of "Amendment Date" is hereby added as Section 1.23 as follows: 

        "Amendment Date" shall mean July 2, 2004. 

      2.2.6  A
new definition of "Amendment Effective Date" is hereby added as Section 1.24 as follows: 

        "Amendment Effective Date" shall mean the date upon which the shareholders of Aventis SA shall have sold to Sanofi-Synthelabo, and
Sanofi-Synthelabo shall have purchased from the shareholders of Aventis SA, more than fifty percent (50%) of the shares and voting rights of Aventis SA in furtherance of the tender offer launched by
Sanofi-Synthelabo with respect to Aventis SA on the terms set forth in the "Note d'Information" that received approval of the French "Autorites des Marches Financiers", as the same may be amended. 

         2.3  The
existing Section 2.1 shall be made Section 2.1(a) and a new Section 2.1(b) is hereby added as follows: 

        Within
ten (10) Business Days of the Amendment Effective Date, Aventis shall assign all right, title and interest to the Additional Patents to Sepracor pursuant to an assignment
substantially in the form attached hereto as Schedule 2.1(b) and shall deliver such executed assignments to Sepracor within such ten
(10) Business Day period. Within twenty (20) Business Days of execution and delivery by Aventis of such assignment, up to date copies of all underlying prosecution history files of the
RPR Application and the Additional Patents not previously provided to Sepracor shall be transmitted to Sepracor. Sepracor may, at its sole discretion, attend to filing and recordation of such
assignments with the applicable patent office(s) in the applicable jurisdiction(s). 

         2.4  Section 2.2
is hereby amended by adding the following phrase at the end of the first sentence: 

        and,
as of the Amendment Effective Date, an exclusive license (exclusive even as to Aventis and its Affiliates except as provided under Section 2.9) under the RPR
Know-How and Improvements to develop, have developed, make, have made, use, market, sell, offer for sale, have sold and distribute Product in the Additional Territory. 

         2.5  Section 2.2
is hereby further amended by (i) adding the phrase "or, as of the Amendment Effective Date, the Additional Territory" after the term
"Territory" in the last sentence of Section 2.2 

2

 

and
(ii) replacing the phrase "Section 2.7" with the phrase "Section 2.9" in the first parenthetical in the first sentence of Section 2.2. 

         2.6  Section 2.3
is hereby amended by adding the phrase "or, as of the Amendment Effective Date, the Additional Territory" after the term "Territory" in the last line
of Section 2.3 and by deleting the word "European" in Section 2.3. 

         2.7  Section 2.7
is hereby deleted in its entirety. 

         2.8  A
new Section 2.9 is hereby added to the Agreement as follows: 

        Aventis
hereby reserves, and nothing in this Agreement shall impair or limit, Aventis' or its Affiliates' or sublicensees' rights under the RPR Know-How and Improvements to
make or have made pharmaceutical products other than Product, or subject to Article 26, to otherwise utilize the RPR Know-How and Improvements for any purposes which are not
expressly and exclusively granted to Sepracor pursuant to the terms of this Agreement, including without limitation for the purposes of meeting and otherwise fulfilling all of Aventis' (and its
Affiliates' and sublicensees') legal, regulatory and contractual obligations with respect to (±) zopiclone in the Additional Territory. 

         2.9  Section 3.2.4
is hereby deleted in its entirety. 

       2.10  Section 5.2
is hereby amended by adding the phrase, "in the Territory" after the phrase "to avoid loss of any rights" in the first sentence of
Section 5.2. 

       2.11  Section 5.3
is hereby deleted in its entirety, and a new Section 5.3 is added in lieu thereof which reads in its entirety as follows: 

        After
the Effective Date, Aventis shall provide Sepracor full access to the information referenced in Section 2.3 hereof, and shall use good faith reasonable efforts in fully
cooperating with Sepracor in order to enable Sepracor to obtain Regulatory Approval of Products. At Sepracor's request, Aventis shall disclose to Sepracor in writing, or via mutually acceptable
electronic media, copies or reproductions of all written RPR Know-How reasonably available to Aventis or its Affiliates in order to enable Sepracor to obtain Regulatory Approval of
Products. In addition, during the term of this Agreement, Aventis shall promptly disclose to Sepracor in writing, or via mutually acceptable electronic media, on an ongoing basis copies or
reproductions of all Improvements that are reasonably necessary to research, develop, register, manufacture, market, use or sell Product. Such Improvements shall be automatically deemed to be within
the scope of the licenses granted herein without payment of any additional compensation. Sepracor shall have the right to use for all purposes in connection with Regulatory Approval (or other
regulatory approval in the Additional Territory) or any regulatory application for Product all RPR Know-How and other information disclosed pursuant to this Section and under this
Agreement. Upon Sepracor's request, Aventis shall provide reasonable technical assistance to enable Sepracor to utilize RPR Know-How to
obtain Regulatory Approval of Products, and from time to time at Sepracor's reasonable request, Aventis shall use good faith reasonable efforts to assist Sepracor in providing responses to questions
that may be raised by regulatory authorities in connection with Sepracor's applications for Regulatory Approval of Products. Sepracor shall be solely responsible for obtaining all Regulatory Approvals
(and other regulatory approvals in the Additional Territory) related to the Product. 

       2.12  Article 6
(Infringement) is hereby amended by adding the phrase "or the Additional Patents, as applicable" after the term "RPR Applications" each time such term
appears in Article 6. 

3

 

       2.13  Article 8
(Term) is hereby deleted in its entirety, and a new Article 8 is added in lieu thereof which reads in its entirety as follows: 

 ARTICLE 8—TERM  

        This Agreement will commence as of the Effective Date and, unless sooner terminated as provided hereunder, shall terminate on the expiration of the royalty
obligations of Article 3, after which time Sepracor will have a fully paid-up, royalty-free and irrevocable exclusive license under RPR Know-How and
Improvements to develop, have developed, make, have made, use, market, sell, offer for sale, have sold and distribute Product in the Territory and the Additional Territory. Notwithstanding the
foregoing, if Sepracor breaches its obligations under Section 2.4, then this Agreement shall terminate ten (10) years from the Effective Date, or thirty (30) days after Aventis
gives notice to Sepracor of such breach, as applicable. Upon any such early termination of this Agreement, all rights to RPR Know-How and Improvements licensed hereunder to Sepracor shall
revert to Aventis, and Sepracor and its Affiliates and Licensees shall make no further use of the same. 

       2.14  Section 10.1.5
is hereby amended by adding the following clause at the end of such Section 10.1.5: 

        As
of the Amendment Date, Aventis' right, title and interest in the Additional Patents, or RPR Know-How as it relates to (+) zopiclone, in the Additional Territory are not
assigned, transferred, or conveyed to a Third Party or, to Aventis' knowledge, otherwise encumbered by a Third Party; 

       2.15  Section 10.1.6
is hereby amended by adding the following clause at the end of such Section 10.1.6: 

As
of the Amendment Date, Aventis is the sole and exclusive owner of the Additional Patents and, to Aventis' knowledge, the sole and exclusive owner or licensee of the RPR Know-How as it
relates to (+)zopiclone, all of which to the knowledge of Aventis, are free and clear of any liens, charges and encumbrances and, to the knowledge of Aventis, except for Aventis' Affiliates, no other
person, corporate or other private entity or governmental entity or subdivision thereof has, or shall have, any claim of control with respect to the Additional Patents, and RPR Know-How as
it relates to (+) zopiclone, in the Additional Territory; 

       2.16  Section 10.1.7
is hereby amended by adding the following clause at the end of such Section 10.1.7: 

        As
of the Amendment Date, in the Additional Territory, there are no claims, judgments or settlements against or owed by Aventis pending or, to the knowledge of Aventis, threatened with
respect to the Additional Patents and the RPR Know-How, as they relate to Zopiclone Technology or Product; 

       2.17  Section 10.1.10
is hereby amended by adding the following clause at the end of such Section 10.1.10: 

        As
of the Amendment Date, Aventis has not performed any searches to determine if, and has no actual knowledge that, the development, manufacture, use, distribution, marketing, promotion
and sale of Compound in the Additional Territory interferes or infringes on any intellectual property rights owned or possessed by any Third Party; and 

       2.18  A
new Section 10.1.12 is hereby added as follows: 

Aventis
and its Affiliates (and any employee, consultant, or agent thereof) shall not directly or indirectly take any action, or cause any action to be taken, between the Amendment Date and 

4

 

the
Amendment Effective Date that is inconsistent with or would alter the correctness of Aventis' representations and warrants in this Agreement. 

       2.19  Section 10.3
is hereby deleted in its entirety and hereby replaced with a new Section 10.3 as follows: 

        During
the term of this Agreement, Aventis covenants that neither Aventis nor any of its Affiliates will develop, use, market, promote, sell or distribute (or agree with any third party
to do any of the foregoing) in the Territory any product containing Compound, the racemate or the other enantiomer thereof, as an active ingredient. 

       2.20  Article 11
(Adverse Events) is hereby amended and restated in its entirety as follows: 

        Following
the Effective Date, Sepracor shall be solely responsible for complying with all legal and/or regulatory obligations in the Territory regarding the reporting of adverse events
related to Product and following the Amendment Effective Date, Sepracor shall be solely responsible for complying with all legal and/or regulatory obligations in the Additional Territory regarding the
reporting of adverse events related to Product. 

       2.21  Section 12.1
is hereby amended by adding the phrase "or the Additional Territory" after the term "Territory" in Section 12.1. 

       2.22  Article 15
(Notices) is hereby amended by replacing the existing notice address for Aventis with the following address: 

Aventis
Pharma SA 

c/o
Aventis Pharmaceuticals Inc.

Mail Stop: BX2-716A

200 Crossing Boulevard, P.O. Box 6890

Bridgewater, NJ 08807-0890

Attn: Vice President Business Development/TL&A

Facsimile: (908) 231-4480 

       2.23  Section 23.2
is hereby amended by deleting the phrase "in the Territory," in the third line of Section 23.2. 

       2.24  A
new Article 26 is hereby added as follows: 

 ARTICLE 26—INFORMATION  

        From and after the Amendment Effective Date, Aventis shall ensure that Aventis and its Affiliates (and employees, consultants, and agents thereof) do not,
directly or indirectly, use or otherwise place in the public domain, any information owned by, or in the possession or control of (including without limitation information relating to Compound or any
metabolites thereof provided by Sepracor to Aventis or its Affiliates), Aventis or its Affiliates that is not in the public domain, specifically relating to Compound (to the extent such exists as of
the Amendment Date) or (±) zopiclone, or any metabolite of either, including but not limited to information relating to research, development, pharmacological
characteristics, clinical effect, clinical trials, manufacture, marketing, commercialization, distribution, importation, exportation, cost, pricing, supply, sales, sales support, or use thereof;  provided, however, that in the Additional Territory, any current or future employees and agents of
Aventis or its Affiliates involved in research, development, manufacture, sales, marketing, promotion, medical communications, or regulatory maintenance of pharmaceutical products containing
(±) zopiclone in the Additional Territory, shall be free to use any Aventis information specifically relating to (±) zopiclone
solely in connection with those activities in the Additional Territory. For purposes of clarity, in no event shall the foregoing prohibit or in any way limit (i) the rights of Aventis or its
Affiliates to use, directly or 

5

 

indirectly,
such information in connection with any actual or proposed sale, assignment or other transfer of rights in (±) zopiclone from Aventis or its Affiliates to
a Third Party (a "Transferee") or (ii) the rights of any Transferee to use, directly or indirectly, such information. Notwithstanding anything to the contrary contained herein,
(i) Aventis, its Affiliates and any employee, agent, or consultant of Aventis, shall be allowed to use, directly or indirectly, such information as required by any applicable law or any
applicable regulatory authority or other governmental entity in the Additional Territory and (ii) the provisions of this Article 26 shall not exclude use of any information independently
developed by Sanofi-Synthelabo or its Affiliates prior to the Amendment Effective Date. 

       2.25  The
following schedules are hereby added as schedules to the 1999 Agreement: 

    2.25.1  Schedule 1.21
attached hereto is hereby added to the 1999 Agreement as Schedule 1.21. 

    2.25.2  Schedule 2.1(b)
attached hereto is hereby added to the 1999 Agreement as Schedule 2.1(b). 

       2.26  Except
as otherwise set forth herein, the 1999 Agreement shall remain in full force and effect. 

ARTICLE 3  

 ADDITIONAL OBLIGATIONS OF AVENTIS  

         3.1  Aventis
shall, within twenty (20) Business Days of the Amendment Effective Date, deliver copies of the documents described on Schedule 3.1 hereto to
Sepracor, to the extent Aventis has not previously delivered copies of such documents, solely to the extent such documents are within the possession or control of Aventis (or its Affiliates, agents,
employees or consultants) on the Amendment Date and are legally permitted to be disclosed. 

         3.2  Within
ten (10) Business Days after the Amendment Date, Aventis shall provide Sepracor with (i) a current docket listing and description of the status of
each of the Additional Patents and copies of all related outstanding actions, if any and (ii) a copy of the prosecution history of any pending applications among the Additional Patents, if any.
From and after the Amendment Date until the earlier of (x) the Amendment Effective Date and (y) the date, if any, that it is determined by Aventis and communicated to Sepracor that the
Amendment Effective Date will not occur, Aventis shall conduct maintenance and prosecution of the Additional Patents consistent with Aventis' past practice and otherwise in the ordinary course of
business, provided, however, that Aventis shall timely pay any taxes, annuities, or maintenance fees due
between the Amendment Date and the Amendment Effective Date. 

ARTICLE 4  

 CONSENT TO ASSIGNMENT  

         4.1  Pursuant
to the terms of Section 18.1 of the 1999 Agreement, Sepracor hereby consents to the assignment by Aventis of Aventis' rights, in whole or in part, under
Article 3 and Article 4 of the 1999 Agreement, as amended by this Amendment, including, without limitation, its right to receive Royalties pursuant to Section 3.1, its right to
receive Royalty Statements pursuant to Section 4.1 and its right to conduct audits pursuant to Section 4.5. 

         4.2  In
connection with the foregoing consent to assignment, Aventis shall have the right to provide complete and unredacted copies of the 1999 Agreement and this Amendment
to any potential assignee, provided, however, that such potential assignee agrees to be bound by confidentiality provisions substantially similar to those set forth in Article 7 of the 1999
Agreement. 

6

 

ARTICLE 5  

 EFFECTIVE DATE  

         5.1  Except
with respect to the provisions of Sections 2.18, 2.22, 3.2 and 4.2 of this Amendment which shall be effective as of the Amendment Date, this Amendment shall
become effective on the date upon which the shareholders of Aventis SA shall have sold to Sanofi-Synthelabo, and Sanofi-Synthelabo shall have purchased from the shareholders of Aventis SA, more than
fifty percent (50%) of the shares and voting rights of Aventis SA in furtherance of the tender offer launched by Sanofi-Synthelabo with respect to Aventis SA on the terms set forth in the "Note
d'Information" that received approval of the French "Autorites des Marches Financiers", as the same may be amended (the "Purchase Event"). Notwithstanding the foregoing, to the extent an event occurs
which would require payment of $5,000,000 under Section 3.2.4 of the 1999 Agreement following the Amendment Date, but prior to the Amendment Effective Date, no such payment shall be made unless
it is determined by Aventis and communicated to Sepracor that the Amendment Effective Date will not occur (the date such notice is communicated, the "Termination
Date"), in which event such payment shall be made within (10) Business Days following the Termination Date. 

[NO FURTHER TEXT ON THIS PAGE]  

7

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first above written. 

	AVENTIS PHARMA SA
	

By:	
 	

/s/  DIRK OLDENBURG      

	Name:	 	Dirk Oldenburg
	Title:	 	General Counsel
	
SEPRACOR INC.
	

By:	
 	

/s/  WILLIAM E. YELLE      

	Name:	 	William E. Yelle
	Title:	 	VP, Business Development

SCHEDULE 1.21  

 ADDITIONAL PATENTS  

	Country
 
	 	Application Date
	 	Application Number
	 	Grant date
	 	Patent Number
	 	Expiration date

	AR	 	16/01/1992	 	321649	 	31/05/1995	 	248024	 	31/05/2010
	AT	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	E 121089	 	16/01/2012
	AU	 	16/01/1992	 	92 12264	 	07/01/1997	 	671797	 	16/01/2012
	BD	 	15/01/1992	 	92 5	 	14/01/1993	 	1002434	 	17/01/2007
	BE	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	BY	 	17/05/1994	 	1681	 	14/05/1997	 	1854	 	16/01/2012
	CA	 	16/01/1992	 	2099782	 	03/12/2003	 	2099782	 	16/01/2012
	CH	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	CZ	 	16/01/1992	 	93 1380	 	02/04/1996	 	281011	 	16/01/2012
	DE	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	69202060.8	 	16/01/2012
	DK	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	ES	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	2071486	 	16/01/2012
	FI	 	16/01/1992	 	93 3248	 	14/11/1997	 	100331	 	16/01/2012
	FR	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	GB	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	GR	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	HU	 	16/01/1992	 	P93 02063	 	02/10/2000	 	218928	 	16/01/2012
	IE	 	16/01/1992	 	92 126	 	21/11/1995	 	66110	 	16/01/2012
	IL	 	16/01/1992	 	100677	 	28/02/1996	 	100677	 	16/01/2012
	IT	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	LU	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	MA	 	15/01/1992	 	22677	 	01/10/1992	 	22392	 	15/01/2012
	MX	 	16/01/1992	 	92 180	 	12/08/1994	 	175679	 	16/01/2012
	NG	 	16/01/1992	 	92 15	 	30/07/1992	 	RP 11252	 	16/01/2012
	NL	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	NO	 	16/01/1992	 	93 1919	 	08/01/1997	 	179911	 	16/01/2012
	NZ	 	15/01/1992	 	241313	 	20/07/1993	 	241313	 	15/01/2012
	OA	 	16/01/1992	 	60387	 	15/04/1994	 	9807	 	16/01/2012
	PH	 	16/01/1992	 	43784	 	23/12/1997	 	30982	 	23/12/2014
	PK	 	16/01/1992	 	92 22	 	19/12/1993	 	132928	 	16/01/2008
	PL	 	16/01/1992	 	P 299834	 	01/02/1995	 	166976	 	16/01/2012
	PT	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	RU	 	16/01/1992	 	93 051787	 	10/05/1998	 	2110519	 	16/01/2012
	SE	 	16/01/1992	 	92903994.9-2101	 	12/04/1995	 	609210	 	16/01/2012
	SK	 	16/01/1992	 	93 719	 	18/02/1998	 	279060	 	16/01/2012
	TN	 	17/01/1992	 	92 004	 	06/10/1992	 	16531	 	17/01/2012
	YU	 	17/01/1992	 	92P 55	 	11/06/2002	 	48 878	 	17/01/2012
	ZA	 	15/01/1992	 	92 302	 	28/10/1992	 	92 302	 	15/01/2012

SCHEDULE 2.1(b)  

 ASSIGNMENT OF ADDITIONAL PATENTS  

ASSIGNMENT  

WHEREAS,
Aventis Pharma SA ("Aventis"), a French corporation having a place of business at 20, avenue Raymond-Aron, F-92160 Antony, France, owns, by assignment, all right,
title, and interest in and to French Patent Application Serial No. 91-00490, entitled "Optically Active 5H-Pyrrolo[3,4-b] pyrazine Derivative,
Its Preparation and Pharmaceutical Compositions Containing Same", and PCT International Patent Application No. PCT/FR92/00031, and any and all non-United States patents or patent
applications related to either of the aforesaid applications, including without limitation the patents and patent applications listed in Attachment A, and any invention described therein (collectively
hereinafter "Eszopiclone Foreign Patents"); and 

WHEREAS,
Sepracor Inc. ("Sepracor"), a Delaware corporation having a place of business at 84 Waterford Drive, Marlborough, Massachusetts USA 01752, is desirous of obtaining Aventis' entire
right, title, and interest in, to, and under the Eszopiclone Foreign Patents, and Aventis desires to assign to Sepracor its entire right, title and interest in the same. 

NOW
THEREFORE, be it known that, for good and valuable consideration to Aventis, the receipt and sufficiency of which is hereby acknowledged, Aventis hereby sells, assigns, transfers, and sets over to
Sepracor, its lawful successors and assigns, Aventis' entire right, title, and interest in, to, and under Eszopiclone Foreign Patents (all of which are hereby incorporated by reference as if fully set
forth herein), any inventions described or claimed therein, all rights to claim priority on the basis of any Eszopiclone Foreign Patents, and all applications for Letters Patent that may be filed for
such invention in any country other than the United States and all Letters Patent that may be granted on any such application, and any and all extensions, supplemental protection certificates,
additions, divisions, substitutions, and renewals of any of the foregoing, in each case, as fully and entirely as the same would have been held and enjoyed by Aventis if this assignment had not been
made. 

AND,
AVENTIS HEREBY further convenants that Aventis shall, from time to time after the date hereof upon the request of Sepracor, execute and deliver to Sepracor such further conveyance instruments or
confirmatory assignments as may be necessary or desirable to evidence more fully the transfer of ownership of all Eszopiclone Foreign Patents to Sepracor, or the original ownership of all the
Eszopiclone Foreign Patents on the part of Aventis, to the fullest extent possible, and to perform any other acts deemed necessary to carry out the intent of this instrument. 

AND,
AVENTIS HEREBY authorizes and requests that any official of any country whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as
aforesaid, to issue all patents or Letters Patents for this invention to Sepracor, its successors and assigns, in accordance with the terms of this instrument. 

        IN
WITNESS WHEREOF, Aventis has caused its authorized representative to execute this Assignment 

	AVENTIS PHARMA SA	 	 	 	 
	

By:	
 	

 	
 	

Date:	
 	

 
	 	 	
	 	 	 	

	Name:	 	 	 	 	 	 
	Title:	 	 	 	 	 	 

 

	State of	 	)	 	 
	 	 	)	 	SS.:
	County of	 	)	 	 

        On this            day
of                        , 2004, before me, a Notary Public in and for the State and County aforesaid, personally
appeared                        ,
to me known and known to me to be the person of that name, who signed and sealed the foregoing instrument, and he acknowledged the same to be his free act and deed. 

	 	 	
	 	,
	 	 	Notary Public.

ATTACHMENT A  

	1.	 	French Patent Application No. 91-00490, filed 17 January 1991;
	2.	 	PCT International Patent Application No. PCT/FR92/00031, filed 16 January 1992;
	3.	 	European Patent Application No. 92903994.9-2101, filed 16 January 1992;
	4.	 	Argentinian Patent No. 248024, granted 31 May 1995;
	5.	 	Austrian Patent No. E 121089, granted 12 April 1995;
	6.	 	Australian Patent No. 671797, granted 7 January 1997;
	7.	 	Bangladesh Patent No. 1002434, granted 14 January 1993;
	8.	 	Belgian Patent No. 609210, granted 12 April 1995;
	9.	 	Belarus Patent No. 1854, granted 14 May 1997;
	10.	 	Canadian Patent No. 2,099,782, granted 3 December 2003;
	11.	 	Swiss Patent No. 609210, granted 12 April 1995;
	12.	 	Czech Republic Patent No. 281011, granted 2 April 1996;
	13.	 	German Patent No. 69202060.8, granted 12 April 1995;
	14.	 	Danish Patent No. 609210, granted 12 April 1995;
	15.	 	Spanish Patent No. 2071486, granted 12 April 1995;
	16.	 	Finnish Patent No. 100331, granted 14 November 1997;
	17.	 	French Patent No. 609210, granted 12 April 1995;
	18.	 	British Patent No. 609210, granted 12 April 1995;
	19.	 	Greek Patent No. 609210, granted 12 April 1995;
	20.	 	Hungarian Patent No. 218928, granted 2 October 2000;
	21.	 	Ireland Patent No. 66110, granted 21 November 1995;
	22.	 	Israeli Patent No. 100677, granted 28 February 1996;
	23.	 	Italian Patent No. 609210, granted 12 April 1995;
	24.	 	Japanese Patent Application No. 1992-504006, filed 16 January 1992;
	25.	 	Luxembourg Patent No. 609210, granted 12 April 1995;
	26.	 	Moroccan Patent No. 22392, granted 1 October 1992;
	27.	 	Mexican Patent No. 175679, granted 12 August 1994;
	28.	 	Nigerian Patent No. RP 11252, granted 30 July 1992;
	29.	 	Netherlands Patent No. 609210, granted 12 April 1995;
	30.	 	Norwegian Patent No. 179911, granted 8 January 1997;
	31.	 	New Zealand Patent No. 241313, granted 20 July 1993;
	32.	 	OAPI Patent No. 9807, granted 15 April 1994;
	33.	 	Philippine Patent No. 30982, granted 23 December 1997;
	34.	 	Pakistan Patent No. 132928, granted 19 December 1993;
	35.	 	Polish Patent No. 166976, granted 1 February 1995;
	36.	 	Portuguese Patent No. 609210, granted 12 April 1995;
	37.	 	Russian Federation Patent No. 2110519, granted 10 May 1998;
	38.	 	Swedish Patent No. 609210, granted 12 April 1995;
	39.	 	Slovakian Patent No. 279060, granted 18 February 1998;
	 	 	 

	40.	 	Tunisian Patent No. 16531, granted 6 October 1992;
	41.	 	Yugoslavian Patent No. 48 878, granted 11 June 2002; and
	42.	 	South African Patent No. 92 302, granted 28 October 1992.

SCHEDULE 3.1  

 ADDITIONAL DOCUMENTATION  

        Draft or completed reports of any clinical or nonclinical studies or experiments not published or previously provided to Sepracor as of the Amendment Effective
Date, including postmarketing reviews and safety surveillance reports relating to Compound, the racemate, the other enantiomer thereof, or metabolites of any of the foregoing. 

QuickLinks

Exhibit 10.1

AMENDMENT AND PATENT ASSIGNMENT AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}]]